



# Stratified Medicine in the UK

## Vision and Roadmap



# Stratified Medicine in the UK Vision and Roadmap

## Summary

A consortium of government bodies and leading charities has joined forces to accelerate the development and uptake of stratified medicine in the UK. The Technology Strategy Board, Medical Research Council (MRC), Cancer Research UK (CRUK), Arthritis Research UK (ARUK), Department of Health (DH), Scottish Government Health Directorate (SGHD) and National Institute for Clinical Health and Excellence (NICE) have formed a partnership to take forward the Stratified Medicine Innovation Platform. Together they will invest around £200m over five years in the area of stratified medicine. Stratified medicine can be summarised as identifying the right therapy for the right patient at the right time in the right dose.

This publication sets out a shared vision for the UK to be the best place to develop, and have adopted, stratified medicine. It also outlines a technology roadmap that describes nine thematic areas which, if advanced successfully, will help accelerate the development and uptake of stratified medicine in the UK. The vision and roadmap grew out of a series of workshops attended by more than 100 people representing a broad range of stakeholders

## Background

Even the best medicines are not equally effective in all patients. Disease processes and treatment choices can vary from person to person even though they may have similar symptoms. It is estimated that only 30-70% of patients respond positively to any particular drug. Recent advances in science, particularly in molecular biology and genomics, mean that it will become increasingly possible to identify the underlying molecular mechanisms of disease. Developing diagnostic tests that indicate the molecular cause of a disease enables the development of new treatments that can more precisely target the disease, as Herceptin does for certain forms of breast cancer. Predicting in advance which groups of patients will respond to a particular therapy and providing treatment accordingly is known as stratified medicine (or personalised medicine).

Across the world, healthcare models are facing greater challenges, both physically and financially, in providing for a growing, ageing population with an increasing burden of disease. The upward trend in spending means healthcare is becoming a more and more significant part of a nation's GDP, and the long-term sustainability of current models of provision is increasingly questioned. A stratified approach has the potential to address some of these issues and at the same time improve patient outcomes.

Costs are increasing too for the supply side. Pharmaceutical R&D productivity is decreasing, meaning higher costs for

fewer new drugs. Data shows that, starting with 5,000-10,000 candidate molecules, it can take up to 15 years, and cost more than \$800m, to get one new drug to market. The sustainability of this model of drug development is increasingly being questioned and many suggest that using molecular biology to select likely responders could lead to reduced development times, fewer failures, and lower costs. Diagnostics companies are an important part of the solution, but developing and commercialising robust tests can be expensive and difficult.

## Stratified Medicine Innovation Platform

Global society faces many challenges. By applying technology and innovation we can help to meet these challenges and, at the same time, open up new opportunities for business. Innovation platforms focus on specific societal challenges where government is taking action through policy, regulation, procurement or fiscal measures. By improving co-ordination between the key players from industry, academia and government, innovation platforms can identify barriers to meeting the challenge, map possible routes to overcoming the barriers, and align activities to support innovative solutions. The aim is to deliver a step change in the ability of UK businesses to provide solutions for the global marketplace, boost UK economic performance, and provide higher-quality, better value healthcare services.

The Stratified Medicine Innovation Platform (SMIP) seeks to build on the UK's strength within global healthcare industries and put it at the centre of the next generation of medicine. It is a five-year programme to accelerate the development and uptake of stratified products and services. The innovation platform is a consortium of seven partner organisations all working towards a common vision. The partners are Technology Strategy Board, Medical Research Council (MRC), Cancer Research UK (CRUK), Arthritis Research UK (ARUK), Department of Health (DH), Scottish Government Health Directorate (SGHD) and National Institute for Health and Clinical Excellence (NICE). Each of these partners in the programme management group serves a different constituency but each has agreed to align activities towards a common goal with benefits for all stakeholders. Together they will invest around £200m in stratified medicine.

Achieving the rapid development and uptake of stratified medicine in the UK will be a difficult and complex task. It needs all components of the UK infrastructure to work together around a common plan and towards a common goal. The SMIP has started the process of building a shared vision for stratified medicine in the UK and a plan to achieve it. An early statement of a UK vision was refined and validated through widespread community engagement, including through workshops where more than a hundred people from more than 70 organisations helped to shape and refine the vision and plan.

This document presents a summary of the views heard from these sessions in the form of a UK Vision for Stratified Medicine in 2025, and a roadmap to achieve it. It attempts to capture some of the excellent stratification-related activity currently going on in the UK, but cannot claim to be comprehensive or an agreed consensus from all of the represented groups. The current version of the roadmap is a starting point. It will constantly evolve as new people contribute to it, and better understanding is developed. Those interested in engaging further with the SMIP are encouraged to join the special interest group on **\_Connect** (<https://ktn.innovateuk.org/web/stratified-medicines-innovation-platform>).

## A Shared Vision

The vision is for the UK to be the best place to develop, and have adopted, stratified medicine. This will benefit patients by improving outcomes, help physicians to select the most appropriate therapies, increase the cost-effectiveness of health service provision and help business to innovate more successfully.

This vision was developed over a series of workshops which explored what the UK landscape should look like in 2025. The key aspects of the vision are given in the box below:

### A UK Vision for Stratified Medicine

- The UK should be the best place to develop, and have adopted, stratified medicine. This will benefit patients, provide cost-effective solutions for the NHS and other healthcare providers and create opportunities for business
- There should be an increased collaborative culture throughout the sector based around shared resources, and systems should be in place for effective data collection, sharing, governance and use across sectors (including NHS, business, academia, regulators and NICE)
- It should be quicker and less expensive to develop new drug-diagnostic combinations and have them licensed, and success should be reflected in increased UK economic growth
- It should be possible for all NHS patients to be involved in medical research if they wish, including through use of patient information and records, in order to inform the next generation of successful therapies
- There should be a smooth reimbursement process for stratified therapies and diagnostics, and an intellectual property (IP) framework that encourages innovation
- The UK health system should have established stratified care pathways, and evidence should be available to show that patient outcomes are improved where stratified medicine is used

## A Shared Roadmap

A technology roadmap identifies the long-term objectives in an area and seeks to understand the possible routes to satisfy them. It can be used to guide the development of new products, processes or services, and to help shape the future direction of an emerging technology. Developing a roadmap has three major uses. It helps reach a consensus about a set of needs and identifies a range of possible solutions to satisfy them; it provides a mechanism to help forecast the required deployment of those solutions; and it provides a framework to help plan and coordinate technology and system developments.

The stratified medicine roadmap describes thematic areas which, if advanced successfully, will help accelerate the development and uptake of stratified medicine in the UK. The themes were identified at a series of workshops attended by a broad stakeholder community that included commercial companies developing therapeutics, diagnostics and data handling solutions; medical charities; and representatives from the healthcare sector including clinicians from across a number of therapeutic areas, pathologists, commissioners, managers and representatives of public sector bodies. In addition, there were academics representing research in all of the main topics around stratification of patients. The roadmap captures the range of views expressed by this broad group of stakeholders. It calls for activity in nine thematic areas.

## The UK Stratified Medicine Roadmap: The Nine Themes

1. Incentivising adoption
2. Increasing awareness
3. Patient recruitment – consents and ethics
4. Clinical trials
5. Data – collection, management and use
6. Regulation and standards
7. Intellectual property
8. Bio-banks and biomarkers
9. Increasing the impact of R&D investment

The UK Stratified Medicine Roadmap contains a panel for each of these themes. Each panel describes how things are perceived to be now and articulates a vision of how they might be in 2025. Some of the barriers to achieving this vision are presented and activities that would accelerate the development of stratification are proposed. Some of the excellent work already in train is highlighted. Many topics are closely interlinked and some occur in more than one panel: for a stratified medicine system to work effectively in the UK, many of these issues will have to be progressed at the same time. The Stratified Medicine Innovation Platform on its own will not be able to achieve everything that needs to be done, but an attempt has been made to show what our own contributions might be. In order to save space in the following panels, acronyms are used. These are detailed in a glossary at the end of the document.

# 1. Incentivising adoption of SM in the NHS

## Current Perceptions

- Reimbursement mechanism for SM related Dx tests not always clear leading to unequal provision
- Slow test adoption - commissioning structure a barrier
- Infrastructure is not equally distributed and may be sub-scale in some locations
- Differing requirements for in-house tests compared to industry developed tests
- Current NHS genetics policy and services not designed for large-scale testing
- Pathology budgets stretched and not linked to care pathways
- Slow adoption of tests without Rx company support

## Barriers

- Budgets and processes in NHS not designed for diagnostic/drug combinations
- Only few clinical decisions based on genetic tests
- Uncertain markets for point of care testing vs. centralised testing
- Dx companies can struggle to provide data for independent NICE assessment
- Uncertain pathology capability in emerging techniques
- Aggressive national pathology cost savings may discourage adoption of new techniques
- No long-term strategic planning in NHS for SM services

## Enablers

- Overall framework development by Human Genomics Strategy Group
- Enhancing NHS informatics capability
- Increasing evidence base leading to more widespread clinical acceptance of the value of genetic tests
- Minimally-invasive biomarker tests
- NICE diagnostics arm is an enabler for value assessment
- National commissioning or funding for stratified medicine, both tests and treatments
- Value assessment of Dx/Rx combinations to inform commissioning

- A smooth integrated system: fair & beneficial to all stakeholders
- Equitable access to the right tests for the right patients at the right time
- Infrastructure available to all with equal access to treatments
- Tests reimbursed at a level that is cost effective and incentivises new development
- Patient/public engagement and acceptance
- Informed commissioning (quality, cost, turnaround etc)

## Future State

## Examples of current UK activity

- NHS/DH initiative to improve cancer gene testing
- HGSG review of commissioning, innovation and service delivery in all genetic medicine
- Ability to use Cancer Drug Fund to buy associated complex diagnostics
- Value-based pricing review of drug procurement in NHS
- SMIP/CRUK SMP large-scale demonstrator programme in cancer
- Pathology modernisation
- Nicholson Review of Innovation in the NHS
- OLS Senior Industry Group addressing business-NHS engagement
- NIHR/NOCRI work to improve access for clinical trials
- Trade Associations (ABPI, BIVDA, ABHI, etc.) work with NHS on new commissioning structures

## Potential Role of SMIP

- Help provide evidence to support policy development for commissioning and procurement
- Help supply chain to develop new business models
- Support health economic assessment of diagnostic testing to inform NHS pricing
- Support CRUK SMP and other demonstrators by funding associated technology development
- Interim support for innovative molecular diagnostics in adoption phase
- Help represent businesses in NHS policy/commissioning development

## 2. Increasing stakeholder awareness

Current Perceptions

Evidence base not conclusive in all therapeutic areas  
 Some patients may see stratification as a method of rationing  
 Variable knowledge of how to apply a test in clinical practice  
 Emerging models for clinical decision support do not always convince clinicians  
 Test usage inconsistent across providers

Barriers

Lack of public awareness of the complexity of gene-medicine interactions  
 Lack of high-quality, clinically approved, education material for patients and practitioners  
 Pace of change of evidence base  
 The difficulty of integrating clinical imaging and laboratory data

Patients understand stratification and accept that treatment access may depend on a complex test  
 Stratification tests included in education materials around patient care pathway  
 Appropriate testing for multiple biomarkers incorporated in clinical care pathway

Future State

Enablers

More awareness among front line staff of clinical utility and benefits  
 Agreement and sharing of genetic medicine health economic analyses  
 Tools for physicians to provide clear interpretation of complex test results  
 Physician-driven development of education materials for healthcare professionals involved in genetic medicine

Development of tests for use at point of prescription (pharmacy/GP) or patients able to test themselves  
 Centralised communication resource to suit a range of health professionals  
 Better engagement with patient support groups in disease specific areas  
 Patient access to global communication channels

### Examples of current UK activity

Education working group of the HGSG  
 Various bodies already developing guidance materials  
 Appointment of NHS Chair in Pharmacogenetics  
 CRUK large-scale demonstrator in cancer

### Potential Role of SMIP

Develop decision-making tools for physicians  
 Develop communication resource for education of health professionals  
 Involve patient support groups and Royal Colleges in SMIP programme development  
 Accelerate and communicate programmes that demonstrate validity of approach  
 Help extend approach into other therapeutic areas

### 3. Patient recruitment (consents & ethics)

**Current Perceptions**

Identifying and recruiting appropriate patient cohorts can be time-consuming  
 R&D approval process can be complex and time-consuming  
 When patient consents are study or site-specific, data cannot be used for other purposes  
 Sometimes local ethics and R&D approval process can inhibit larger national studies  
 Problems with national programme for IT has held back novel data solutions

**Barriers**

Data held in a range of databases and formats across healthcare providers  
 Data quality may be low in data that has not been monitored and audited  
 Inconsistent processes and standards for research consents  
 Privacy concerns around data storage and use  
 Excessive caution from some (unrepresentative) minority pressure groups

**Enablers**

Structure of NHS gives unique opportunity to deliver standardised research consent  
 Novel IT solutions for capturing, communicating, storing and analysing data  
 Public engagement about use of samples and genetic data for research  
 Development of an overarching ethical framework  
 Cost of storing massive data sets decreasing  
 Patient groups support non-restrictive consents and effective R&D approvals  
 Development and widespread use of generic consent forms

Implementation of Academy of Medical Sciences recommendations on streamlining research regulation  
 Connection of ethics committee with patient groups, starting with current disease areas of focus like cancer  
 Policy communication, IT enablement & governance.  
 Education and public awareness campaign demonstrating wider benefits to the community of participation in research  
 Collaboration in clinical trials recognised in clinician performance assessment

A streamlined process for trials consent and patient recruitment, and trials are safe  
 Consent for broad and unspecified future use, supported by appropriate regulation of personal data  
 Single, and internationally valid, consent and ethics approval  
 Primary care has important role in patient recruitment  
 Use of data and samples for research based on 'opt-out' rather than 'opt-in'

**Future State**

#### Examples of current UK activity

Academy of Medical Science report and recommendations  
 Leading hospitals already running generic consent for all patient samples  
 HGSG working on this area  
 Plan for Growth actions on research approvals and recruitment to studies  
 NIHR Translational Research Partnerships process for research consent in inflammatory disease  
 Various data access and sharing initiatives (Generation Scotland, Cancer Registries, General Practice Research Database)  
 Improved national and international data standards are enabling data sharing

#### Potential Role of SMIP

Engage with patient groups on programme development and benefits of consent  
 Support Government implementation of AMS recommendations  
 Consulting with stakeholders on routine/generic consent

## 4. Clinical Trials

### Current Perceptions

Localisation of commissioning and independence of providers leads to varied and complex implementation of national clinical trials

NIHR involve patients group

Networks such as NCRI encourage and enable national trials

Delays before patient recruitment starts is often the time-limiting step in studies

AMS report describes the situation well

### Barriers

Uncertain impact of localisation agenda in healthcare and changes in commissioning

Relative higher prices for trial activities in UK versus BRIC countries

### Enablers

AMS report and recommendations

National initiatives to improve trials environment (CRUK, NOCRI, etc)

Public increasing their levels of participation in research

Faster ethics approval based on patient choice and critical health 'need'

Reduced time and cost to conduct clinical trials

Reduced time to start complex genetic research projects

Reduced cost to recruit the appropriate subjects to enable stratified medicine

All patients are able to participate in clinical trials/population-based genomic research

Centralised solutions to access rare genetic types (e.g. web-based platform)

Exclusion of inappropriate patient populations on grounds of safety genotypes

Selection of appropriate patients for efficacy testing

### Future State

### Examples of current UK activity

NIHR Clinical Research Networks, including cancer, could help in stratified medicine

NOCRI helping industry engagement with NIHR trials infrastructure

NIHR common frameworks and guidelines to reduce patient recruitment times

### Potential Role of SMIP

Similar to role in patient recruitment

Help create critical mass to accelerate trials process

Communicate unmet needs (prioritisation)

Demonstration of a consistent database of patient accessible records.

Develop web-based recruitment tools



## 5. Data

### Current Perceptions

Routine data collection and quality variable across the UK, better in Scotland  
NHS Information Centre as central repository and access point for data but currently not meeting researcher requirements  
Government data transparency drive (opengov)  
No national programme for IT  
Range of IT systems in use

### Barriers

Morale issues following NPfIT failure  
Most data has not been consented for access  
Default position is to not make anonymised data available for research  
Bespoke systems do not or cannot communicate without significant investment  
Data protection issues seen as a barrier within trusts

Population-wide consented patient data available for analysis by researchers  
Routine use of anonymised patient data sets by NHS & industry to improve patient outcomes  
Increased use of routine data in post-marketing surveillance  
Routine collection of health economic data around SM

### Future State

Massive data sets  
Public support for research  
IT capabilities improving  
Encourage more open working between academia, NHS & industry  
Cultural/policy encouragement to share data

### Enablers

Implement IT practices and routine generic consent for use of appropriately anonymised clinical data for research between institutions  
Large-scale demonstrator programmes (regional or therapeutic-area focused)  
Simplification of data protection rules around patient data  
Build in and embed quality systems into NHS data handling

### Examples of current UK activity

Generation Scotland  
Individual routine consents  
CRUK/Eastern Cancer Registry partnership & SMIP investment in data handling  
Ongoing improvements to cancer registries  
Establishment of Patient Reported Outcome Measures (PROMS) by Dept Health in England

### Potential Role of SMIP

Develop tools to allow secure data mining of patient data across distributed data sources  
Demonstrate that access to data repository by NHS & industry will improve patient outcomes and/or make UK a much better place to do research

## 6. Regulatory Framework and Development Pathway

Current Perceptions

It can cost over \$800m to take a safe and effective drug to market, and take 7-9 years from first in-man trials

New drugs sometimes only marginally better than standard care but more expensive

Different degrees of regulation for pharmaceuticals, diagnostic tests and laboratories/hospitals

### Barriers

Lack of smart and adaptive study designs

Lack of a single body controlling quality of diagnostic labs

Need for regulatory guidance development for drug-diagnostic combinations

### Enablers

Regulatory guidance for co-development of diagnostics and treatment

DH and BIS encouraging EU Commission to improve regulatory framework

Facilitate co-development of drugs and diagnostics by alignment of the regulatory processes

Setting up of an expert committee (akin to the Committee for Advanced Therapies set up by the ATMP Regulation)

Novel design of clinical trials makes smaller cohorts of patients possible

Coordinated regulation of pharmaceuticals industry (Rx) and diagnostic industry (Dx)

Companies make more progress within existing regulatory framework

Future State

### Examples of current UK activity

EU Commission on the revision of the IVD directive

NHS QIPP agenda includes work on quality and standards

### Potential Role of SMIP

Help in novel clinical study design

Encourage discussion with regulatory agencies

# 7. Intellectual Property

Current Perceptions

Laboratory-developed tests using unlicensed IP in NHS discourages development of new diagnostic tests by industry

Laboratory-developed tests can sometimes save the NHS money

Some NHS laboratory-developed tests are being technically and clinically validated and externally quality assured

Current IP for gene sequences (BRCA/Myriad etc) subject to legal challenge

## Barriers

Questions around effective regulation of laboratory-developed tests

No single approach to NHS licensing of test technology

Patent thickets – multiple IP on sequence reduces economic attractiveness of panel testing

IP with enhanced licensing for NHS use acts as a driver of 'step change' innovation

Publicly funded labs are free to develop safe and effective tests that do not infringe on other IP rights-holders

Competition between commercial and laboratory-developed tests benefits patients

Future State

## Enablers

Patent box tax incentive

Excellent technology platform & biomarker science base

Business models for developing & exploiting new & existing IP that provides fair return on investment whilst maintaining reasonable end user cost

Develop IP protection on the test, not the underlying gene sequence

Provide a strong home market (NHS) with value based pricing (product & service) and willingness to adopt new tests

A stronger domestic industry with global outlook, able to capitalise on excellent science base

## Examples of current UK activity

EU In-Vitro Diagnostic consultation in process

OECD guidelines for licensing genetic inventions

HGC recommendations on IP and DNA diagnostics

## Potential Role of SMIP

Provide support for diagnostic companies and co-development

Support SMEs in early IP filing

Commission health economics studies

Support development of new business models and pricing mechanisms

## 8. Bio-Banks and Early Biomarker Detection

Current Perceptions

No central overarching database of biomarkers or biosignatures  
 Many biosamples not clinically annotated  
 Limited standardisation of tissue collection or consent  
 Not everyone sees the value of centralised biobanks  
 Stand-alone, incompatible tissue and data infrastructures  
 UK Biobank has recruited 0.5m people

### Barriers

Localised clinical and research databases are hard to use for national level research  
 Lack of technology platforms for use in clinical biomarker research  
 Require policy framework for biomarker validation  
 Many biomarkers do not have associated therapies

### Enablers

Accreditation system for biobanks  
 Improve coordination of funding for biobanks  
 Standardisation of procedures, including sample handling storage and consent process  
 Ensuring biobanks store comprehensive clinical data  
 Broad & enduring consent or implement opt-out rather than opt-in for data analysis in research

UK-wide database of biobanks is used for stratification studies  
 All tissue collected with consent for broad clinical research and data capture  
 Routine, effective collaboration on biomarker ID  
 A range of early biomarkers identified for future validation  
 Coordination for Biomarker research via mandated central database  
 In silico trials to ID biomarker

Future State

### Examples of current UK activity

UK Biobank programme standardising access procedures  
 Generation Scotland  
 Routine generic consent at sample-acquisition in major teaching hospitals  
 NIHR/NOCRI Translational Research Partnerships

### Potential Role of SMIP

Help develop standards for biobanks  
 Map existing UK databases and biobanks  
 Support development of sample handling & preservation technologies  
 Support development of biosignature analysis and data storage techniques  
 Encourage widespread adoption of best practice  
 Help connect existing infrastructure to create critical mass  
 Enable access to infrastructure to accelerate development of new tests and therapies

# 9. Increasing and Leveraging UK R&D investment

**Current Perceptions**

- Developing new drugs has become increasingly expensive
- Pharmaceutical businesses are re-evaluating their R&D investments
- Turbulence in financial markets has impacted availability of equity and debt finance
- Public sector funders have not always aligned their activities
- University funding is changing
- NHS needs to save money

**Barriers**

- Different parts of the system have different objectives
- Bridging the gap between research and commercial exploitation
- The RAE/REF do not incentivise academics to help commercialisation
- The sector is extremely large and complex, so major change is non-trivial

**Enablers**

- Creating a coordinated UK programme
- Incentivise stakeholders to share pre-competitive data
- Stakeholder support for SM
- Full audit of UK capabilities /IT, biomarkers, Dx, Rx, clinical etc
- Better coordinated UK and EU funding streams
- Understand the value of cooperative investment
- Taking an international perspective

- Taking drugs from discovery phase to commercialisation is faster and cheaper, enhancing business performance and encouraging investment
- Stratified medicine offers improved value for money for customers including NHS
- Improved co-ordination of public and private funding

**Future State**

**Examples of current UK activity**

- ABPI work in this area
- OSCHR work in this area
- Nicholson Review of innovation in the NHS
- NorthWest exemplar
- Stratified Medicine Innovation Platform investments to date

**Potential Role of SMIP**

- Commission health economic studies
- Help develop new business models for stratified medicine
- Ensure coordination of partner activities
- Help create critical mass through a UK-wide programme
- Engage in international programmes

## Stratified Medicine Innovation Platform Partners

The innovation platform seeks to make the UK the best place to develop, and have adopted, stratified medicine products and services. This is an extremely ambitious vision that will require activities across multiple technology areas, policy streams and government departments. Each of the Stratified Medicine Innovation Platform partners has a specific remit and can contribute significant resources and expertise from their core areas of capability. Together, the group covers a broad spectrum of interests. By aligning activities, many of the issues described above can be progressed.

The Technology Strategy Board aims to help businesses to develop innovative new products and services, while the Medical Research Council funds outstanding research in the science base and has a major initiative in stratified medicine. Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research, and Arthritis Research UK has an interest in achieving better outcomes for patients in its disease area: both have stratified medicine at the centre of their strategies. The Department for Health and Scottish Government Health Directorate are government departments whose main role is to improve health and achieve better health, better care, and better value for all. The National Institute for Health and Clinical Excellence is tasked with assessing medical interventions, both therapies and diagnostics, and recommending their use based on value calculations.

The SMIP programme management group would greatly welcome input from other players. The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health Research (NIHR)/ NIHR Office for Clinical Research Infrastructure (NOCRI) have already started working closely with the innovation platform, and it is hoped that others would also like to participate. There will be areas where others are better placed to lead, and we can support their programmes.

## How to engage with us

For the UK to achieve the vision set out in this document, significant advancements in technology and changes to systems and processes will be required. This cannot be achieved by any single organisation and will entail coordinated activity across the entire healthcare sector. This UK Stratified Medicine Vision and Roadmap can form the focal point for companies, public sector bodies and government to coordinate their efforts. The innovation platform partners have begun this coordinated activity and would welcome help and advice from others whose actions could help accelerate the journey towards the ultimate goal. A web-based community has been created to encourage engagement (<https://ktn.innovateuk.org/web/stratified-medicines-innovation-platform>). This will be supported by the innovation platform and will highlight future workshops, funding calls and ongoing discussions on specific stratified-medicine-related topics. We would also encourage others to use this forum to share information, raise awareness, identify partners and generate yet more momentum.

## Glossary

ABHI	Association of British Healthcare Industries
ABPI	Association of British Pharmaceutical Industry
AMS	Academy of Medical Sciences
ATMP	Advanced Therapy Medicinal Products
BIS	UK Department for Business, Innovation & Skills
BIVDA	British In-vitro Diagnostic Association
BRIC	Brazil, Russia, India and China
CRUK	Cancer Research UK
CRUK SMP	Cancer Research UK Stratified Medicine Programme
DH	Department of Health
Dx	diagnostic
HGC	Human Genetics Commission
HGSG	Human Genome Strategy Group
IP	intellectual property
IT	information technology
IVD	in-vitro diagnostic
NCRI	National Cancer Research Institute
NHS	National Health Service
NICE	National Institute for Health and Clinical Excellence
NIHR	National Institute for Health Research
NOCRI	NIHR Office for Clinical Research Infrastructure
NPfIT	National Programme for IT
OECD	Organisation for Economic Co-operation and Development
OLS	Office of Life Sciences
OSCHR	Office for Strategic Co-ordination of Health Research
PROMs	patient reported outcome measures
QIPP	quality, innovation, productivity and prevention
R&D	research and development
RAE/REF	Research Assessment Exercise/Research Excellence Framework
Rx	therapeutic
SM	stratified medicine
SMIP	Stratified Medicine Innovation Platform



Technology Strategy Board  
North Star House  
North Star Avenue  
Swindon  
SN2 1UE

Telephone: 01793 442700

[www.innovateuk.org](http://www.innovateuk.org)